目的 使用文献计量学方法对我国肺癌合并慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的研究现况和主要研究主题进行可视化分析。 方法 计算机检索中国生物医学文献数据库(CBM)、中国知网(CNKI)、万方数据库(WanFang)、The Cochrane Library、EMbase 和 PubMed 数据库,纳入所有关于肺癌合并 COPD 的研究,检索时间均为建库至 2018 年 3 月。采用 BICOMS 分析软件对主要信息进行抽取和整理,生成共现矩阵;采用 gCLUTO 进行聚类分析;采用 UCINET 和 Cytoscape 生成社会网络关系图。 结果 共纳入 304 篇文献,源自 173 种期刊,其中中国科学引文数据库(Chinese Science Citation Database,CSCD)收录 23 种期刊,所刊文献 42 篇,占文献总数的 13.8%,科学引文索引(Science Citation Index,SCI)收录 24 种,所刊文献 37 篇,占文献总数的 12.2%。发文量自 2012 年后呈现快速增长。研究涉及全国 32 个省市、自治区和直辖市,其中以北京市、四川省、广州市、上海市和江苏省为主要研究地区。以频次 2 为阈值获得 69 个高频关键词,双聚类分析将其聚为 5 类,其中,0 类主题表现为肺癌合并 COPD 的发病机制及放射学诊断;1 类主题表现为不同病理类型肺癌合并 COPD 的临床特征及中医治疗研究;2 类主题表现为危险因素对手术并发症的影响及化疗和靶向治疗与患者生存预后关系的研究;3 类主题表现为肺癌与 COPD 的表观遗传学关联;4 类主题表现为肺癌合并 COPD 患者围手术期综合管理的临床研究。 结论 文献计量结果表明我国肺癌合并 COPD 的整体研究成果较多,自 2012 年以来研究逐渐增加,但研究存在严重地域不平衡性;横向研究主题广泛,研究热点以探索肺癌合并 COPD 的围手术期综合管理及基础研究居多,但纵向主题有待进一步深入研究,部分研究结果尚未达成共识,鲜有多中心高质量研究,缺乏临床指导性研究成果。

Objective To explore the research state and topics of lung cancer with chronic obstructive pulmonary disease (COPD) in China using the visualization methods. Methods Literature about lung cancer with COPD was searched through WanFang, CNKI, CBM, PubMed, The Cochrane Library and EMbase databases from inception to March 2018 by computer. We used BICOMS software to analyze the main information and produce co-word matrix, gCLUTO software to cluster, and NetDraw and Cytoscape software to draw the pictures. Results There were 304 studies related to lung cancer with COPD which originated from 173 journals including 23 indexed by Chinese Science Citation Database (CSCD) with 42 articles published, accounting for 13.8% of the total number of studies. There were 37 articles from 24 journals indexed by Science Citation Index (SCI) accounting for 12.2% of the total number of studies. The studies grew rapidly since 2012. The study involved 32 provinces, municipalities, and autonomous regions, among which Beijing, Sichuan, Shanghai, Guangzhou and Jiangsu provinces and cities were the main research areas. Sixty-nine high-frequency keywords were obtained with frequency 2 as the threshold, which was clustered into 5 categories by dual cluster analysis. Among them, topic 0 showed pathogenesis and radiological diagnosis of lung cancer with COPD, topic 1 was about the clinical characteristics of different pathological types of lung cancer with COPD and Chinese medicine treatment, topic 2 aimed at the impact of risk factors on surgical complications and the relationship between chemotherapy or targeted therapies and patient survival prognosis, topic 3 involved the pigenetic correlation between lung cancer and COPD and topic 4 was about clinical studies of perioperative comprehensive management of lung cancer patients with COPD. Conclusion The bibliometrics results show that there are considerable-amount achievements on lung cancer combined with COPD in China, and the researches have gradually increased since 2012. Horizontal research topics are extensive, and the focus of the study is to explore the perioperative comprehensive management and basic research of lung cancer with COPD, but the longitudinal themes need to be further studied. The results of some studies have not yet reached a consensus. There are few high-quality multi-center studies and a lack of clinical-directed achievement.

关键词: 肺癌; 慢性阻塞性肺疾病; 可视化分析; 文献计量; 研究主题

Key words: Lung cancer; chronic obstructive pulmonary disease; visualization analysis; bibliometrics; research topics

引用本文: 高华, 赵晔, 冯海明, 宋铁牛, 杨建宝, 敬涛, 蒋鹏, 蔺军平, 李斌. 基于文献计量学方法分析我国肺癌合并慢性阻塞性肺疾病的研究现状. 中国胸心血管外科临床杂志, 2019, 26(3): 233-244. doi: 10.7507/1007-4848.201803054 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med, 2013, 369(5): 448-457.
2. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med, 2008, 178(7): 738-744.
3. Denholm R, Schüz J, Straif K, et al. Is previous respiratory disease a risk factor for lung cancer? Am J Respir Crit Care Med, 2014, 190(5): 549-559.
4. Smith BM, Pinto L, Ezer N, et al. Emphysema detected on computed tomography and risk of lung cancer: a systematic review and meta-analysis. Lung Cancer, 2012, 77(1): 58-63.
5. Villar Álvarez F, Muguruza Trueba I, Belda Sanchis J, et al. Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer. Arch Bronconeumol, 2016, 52(7): 378-388.
6. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015, 385(9963): 117-171.
7. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917.
8. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J, 2009, 34(2): 380-386.
9. Vineis P, Airoldi L, Veglia F, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ, 2005, 330(7486): 277.
10. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med, 1986, 105(4): 503-507.
11. Calabrò E, Randi G, La Vecchia C, et al. Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. Eur Respir J, 2010, 35(1): 146-151.
12. Schwartz AG, Cote ML, Wenzlaff AS, et al. Chronic obstructive lung diseases and risk of non-small cell lung cancer in women. J Thorac Oncol, 2009, 4(3): 291-299.
13. Henschke CI, Yip R, Boffetta P, et al. CT screening for lung cancer: Importance of emphysema for never smokers and smokers. Lung Cancer, 2015, 88(1): 42-47.
14. Schwartz AG, Lusk CM, Wenzlaff AS, et al. Risk of lung cancer associated with COPD phenotype based on quantitative image analysis. Cancer Epidemiol Biomarkers Prev, 2016, 25(9): 1341-1347.
15. Wang H, Yang L, Zou L, et al. Association between chronic obstructive pulmonary disease and lung cancer: a case-control study in Southern Chinese and a meta-analysis. PLoS One, 2012, 7(9): e46144.
16. Dai J, Yang P, Cox A, et al. Lung cancer and chronic obstructive pulmonary disease: From a clinical perspective. Oncotarget, 2017, 8(11): 18513-18524.
17. Dai J, Liu M, Swensen SJ, et al. Regional emphysema score predicting overall survival, quality of life, and pulmonary function recovery in early-stage lung cancer patients. J Thorac Oncol, 2017, 12(5): 824-832.
18. Dai J, Liu M, Jiang G, et al. The impact of chronic obstructive pulmonary disease on lung cancer survival: A meta-analysis. Arch Cancer Res, 2016, 4: 1.
19. Wasswa-Kintu S, Gan WQ, Man SF, et al. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax, 2005, 60(7): 570-575.
20. Hersh CP, Washko GR, Jacobson FL, et al. Interobserver variability in the determination of upper lobe-predominant emphysema. Chest, 2007, 131(2): 424-431.
21. Li Y, Swensen SJ, Karabekmez LG, et al. Effect of emphysema on lung cancer risk in smokers: a computed tomography-based assessment. Cancer Prev Res (Phila), 2011, 4(1): 43-50.
22. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest, 2007, 132(6): 1932-1938.
23. Lowry KP, Gazelle GS, Gilmore ME, et al. Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis. Cancer, 2015, 121(10): 1556-1562.
24. Biswas A, Mehta HJ, Folch EE. Chronic obstructive pulmonary disease and lung cancer: inter-relationships. Curr Opin Pulm Med, 2018, 24(2): 152-160.
25. Yang P, Sun Z, Krowka MJ, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med, 2008, 168(10): 1097-1103.
26. Zhao B, Han H, Chen J, et al. MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett, 2014, 342(1): 43-51.
27. Van Pottelberge GR, Mestdagh P, Bracke KR, et al. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2011, 183(7): 898-906.
28. Young RP, Whitford W, Hopkins RJ. Telomere shortening in COPD and lung cancer: a pilot study in chronic smokers in D99. Novel translational biomarkers in lung cancers. Am Thoracic Soc, 2016: A7539-A7539.
29. Anzalone G, Arcoleo G, Montalbano AM, et al. Cigarette smoke alters the EZH2/DAB2IP expression in bronchial epithelial cells. A risk factor for lung cancer in COPD patients. Eur Respiratory Soc, 2016, 48(suppl 60): PA3995.
30. Dang X, Ma A, Yang L, et al. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet, 2012, 205(3): 113-123.
31. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol, 2003, 28(5): 555-562.
32. Otsubo K, Goto H, Nishio M, et al. MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation. Oncogene, 2017, 36(29): 4201-4211.
33. Takahashi H, Ogata H, Nishigaki R, et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell, 2010, 17(1): 89-97.
34. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J, 2006, 28(1): 219-242.
35. Covey TM, Edes K, Coombs GS, et al. Alkylation of the tumor suppressor PTEN activates Akt and β-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer. PLoS One, 2010, 5(10): e13545.
36. Ng Kee Kwong F, Nicholson AG, Harrison CL, et al. Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma? Eur Respir Rev, 2017, 26(146): pii: 170040.
37. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 2005, 6(11): 1133-1141.
38. Chen X, Wan J, Liu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer, 2010, 69(3): 348-354.
39. Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer, 2013, 13(4): 233-245.
40. Shapiro SD, Goldstein NM, Houghton AM, et al. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol, 2003, 163(6): 2329-2335.
41. Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest, 2015, 148(4): 971-985.
42. Gershon AS, Hwee J, Chapman KR, et al. Factors associated with undiagnosed and overdiagnosed COPD. Eur Respir J, 2016, 48(2): 561-564.
43. Young RP, Hopkins RJ. Diagnosing COPD and targeted lung cancer screening. Eur Respir J, 2012, 40(4): 1063-1064.
44. de Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. Am J Respir Crit Care Med, 2011, 184(8): 913-919.
45. de-Torres JP, Wilson DO, Sanchez-Salcedo P, et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med, 2015, 191(3): 285-291.
46. Gould MK. Lung cancer screening in individuals with chronic obstructive pulmonary disease. Finding the sweet spot. Am J Respir Crit Care Med, 2015, 192(9): 1027-1028.
47. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: Role of comorbidities. Eur Respir J, 2006, 28(6): 1245-1257.
48. Lung Health Study Research Group, Wise R, Connett J, et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med, 2000, 343(26): 1902-1909.
49. Putila J, Guo NL. Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer. PLoS One, 2014, 9(6): e100994.
50. Hopkins RJ, Ko J, Gamble GD, et al. Lung cancer surgery for early stage non-small cell lung cancer: systematic review of mortality according to the presence of COPD. B110: pulmonary nodules and thoracic surgery: working across the aisle. Am Thoracic Soc, 2017: A4887.
51. Zhai R, Yu X, Shafer A, et al. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest, 2014, 145(2): 346-353.
52. Sekine Y, Suzuki H, Yamada Y, et al. Severity of chronic obstructive pulmonary disease and its relationship to lung cancer prognosis after surgical resection. Thorac Cardiovasc Surg, 2013, 61(2): 124-130.
53. McLeod RS, Aarts MA, Chung F, et al. Development of an enhanced recovery after surgery guideline and implementation strategy based on the knowledge-to-action cycle. Ann Surg, 2015, 262(6): 1016-1025.
54. Benzo R, Wigle D, Novotny P, et al. Preoperative pulmonary rehabilitation before lung cancer resection: results from two randomized studies. Lung Cancer, 2011, 74(3): 441-445.
55. Lai Y, Su J, Yang M, et al. Impact and effect of preoperative short-term pulmonary rehabilitation training on
 lung cancer patients with mild to moderate chronic obstructive pulmonary disease:
A randomized trial. Zhongguo Fei Ai Za Zhi, 2016, 19(11): 746-753.
56. Stefanelli F, Meoli I, Cobuccio R, et al. High-intensity training and cardiopulmonary exercise testing in patients with chronic obstructive pulmonary disease and non-small-cell lung cancer undergoing lobectomy. Eur J Cardiothorac Surg, 2013, 44(4): e260-e265.
57. Borges RC, Carvalho CR. Impact of resistance training in chronic obstructive pulmonary disease patients during periods of acute exacerbation. Arch Phys Med Rehabil, 2014, 95(9): 1638-1645.
58. Ferri L, Cesario A, Margaritora S, et al. Pulmonary rehabilitation in patients undergoing resection for non-small cell lung cancer. A preoperative and postoperative added value. Eur J Cardiothorac Surg, 2008, 33(4): 757-757.
59. Divisi D, Di Francesco C, Di Leonardo G, et al. Preoperative pulmonary rehabilitation in patients with lung cancer and chronic obstructive pulmonary disease. Eur J Cardiothorac Surg, 2013, 43(2): 293-296.
60. Sekine Y, Chiyo M, Iwata T, et al. Perioperative rehabilitation and physiotherapy for lung cancer patients with chronic obstructive pulmonary disease. Jpn J Thorac Cardiovasc Surg, 2005, 53(5): 237-243.
61. Saito H, Hatakeyama K, Konno H, et al. Impact of pulmonary rehabilitation on postoperative complications in patients with lung cancer and chronic obstructive pulmonary disease. Thorac Cancer, 2017, 8(5): 451-460.
62. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage Ⅰ non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2012, 83(1): 348-353.
63. Mokhles S, Verstegen N, Maat AP, et al. Comparison of clinical out- come of stage Ⅰ non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung Cancer, 2015, 87(3): 283-289.
64. Spyratos D, Papadaki E, Lampaki S, et al. Chronic obstructive pulmonary disease in patients with lung cancer: prevalence, impact and management challenges. Lung Cancer (Auckl), 2017, 8: 101-107.
65. Inoue T, Shiomi H, Oh RJ. Stereotactic body radiotherapy for Stage Ⅰ lung cancer with chronic obstructive pulmonary disease: special reference to survival and radiation-induced pneumonitis. J Radiat Res, 2015, 56(4): 727-734.
66. Takeda A, Kunieda E, Ohashi T, et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest, 2012, 141(4): 858-866.
67. Omote N, Hashimoto N, Morise M, et al. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy. Int J Chron Obstruct Pulmon Dis, 2017, 12: 3541-3547.
68. Izquierdo JL, Resano P, El Hachem A, et al. Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors. Int J Chron Obstruct Pulmon Dis, 2014, 9: 1053-1058.
69. 杜建飞, 畅婕, 崔立春, 等. 同步放化疗治疗局部晚期 EGFR 野生型 NSCLC 合并 COP D 患者的临床疗效观察. 中华肺部疾病杂志:电子版, 2017, 10(5): 559-563.
70. 周承志, 秦茵茵, 张洁霞, 等. 氩氦刀联合放疗治疗晚期 EGFR 野生型非小细胞肺癌合并慢性阻塞性肺疾病患者的临床观察. 现代肿瘤医学, 2014, 22(11): 2600-2603.
71. Ma Q, Ma L, Wang Y, et al. Observation of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer and COPD. Zhongguo Fei Ai Za Zhi, 2009, 12(12): 1295-1296.
72. Gao YH, Guan WJ, Liu Q, et al. Impact of COPD and emphysema on survival of patients with lung cancer: A meta-analysis of observational studies. Respirology, 2016, 21(2): 269-279.
73. Chang KC, Leung CC. Lung cancer is more common in early GOLD stages of COPD: a spurious association? Am J Respir Crit Care Med, 2012, 185(10): 1128-1128.
74. Kuo CH, Wu CY, Lee KY, et al. Chronic obstructive pulmonary disease in stage Ⅰ non-small cell lung cancer that underwent anatomic resection: the role of a recurrence promoter. COPD, 2014, 11(4): 407-413.
75. Gao L, Xie S, Liu H, et al. Lung cancer in patients with combined pulmonary fibrosis and emphysema revisited with the 2015 World Health Organization classification of lung tumors. Clin Respir J, 2018, 12(2): 652-658.
76. Wang P, Zhang D, Guo XG, et al. Clinical characteristics and risk factors affecting outcomes of elderly patients with non-small cell lung cancer complicated by chronic obstructive pulmonary disease. Nan Fang Yi Ke Da Xue Xue Bao, 2017, 37(7): 889-894.
77. Wang W, Xu Z, Xiong X, et al. Video-assisted thoracoscopic lobectomy for non-small cell lung cancer in patients with severe chronic obstructive pulmonary disease. J Thorac Dis, 2013, 5(Suppl 3): S253-S259.
78. Zhou Z, Song X, Wu A, et al. Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy. Sci Rep, 2017, 7(1): 2748.